Cogent Biosciences Shares Double On Tumor Drug Positive Trial Results

Dow Jones

2025/11/10

By Nicholas G. Miller

Shares of Cogent Biosciences soared after the company reported positive trial data for its treatment of Gastrointestinal Stromal Tumors that surpassed its expectations.

The stock more than doubled in premarket trading to $30.97 Monday after closing Friday up 90% this year.

In a phase three trial, the company's treatment combining bezuclastinib with sunitinib showed 16.5 months median progression free survival compared to 9.2 months for sunitinib monotherapy. The safety profile was also well tolerated.

"The bezuclastinib combination is poised to become the new standard of care for treatment of second-line GIST patients," said Cogent Chief Executive Andrew Robbins.

The company said it planned to submit a new drug application for bezuclastinib in the first half of next year.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

November 10, 2025 09:08 ET (14:08 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582687216"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582687216\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582687216?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 22:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582687216","market":"sg","top_or_hot":-1,"title":"Cogent Biosciences Shares Double On Tumor Drug Positive Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/COGT\">Cogent Biosciences</a> soared after the company reported positive trial data for its treatment of Gastrointestinal Stromal Tumors that surpassed its expectations. \n</p>\n<p>\n  The stock more than doubled in premarket trading to $30.97 Monday after closing Friday up 90% this year. \n</p>\n<p>\n  In a phase three trial, the company's treatment combining bezuclastinib with sunitinib showed 16.5 months median progression free survival compared to 9.2 months for sunitinib monotherapy. The safety profile was also well tolerated. \n</p>\n<p>\n  \"The bezuclastinib combination is poised to become the new standard of care for treatment of second-line GIST patients,\" said Cogent Chief Executive Andrew Robbins. \n</p>\n<p>\n  The company said it planned to submit a new drug application for bezuclastinib in the first half of next year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 10, 2025 09:08 ET (14:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cogent Biosciences Shares Double On Tumor Drug Positive Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCogent Biosciences Shares Double On Tumor Drug Positive Trial Results\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-11-10 22:08</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/COGT\">Cogent Biosciences</a> soared after the company reported positive trial data for its treatment of Gastrointestinal Stromal Tumors that surpassed its expectations. \n</p>\n<p>\n  The stock more than doubled in premarket trading to $30.97 Monday after closing Friday up 90% this year. \n</p>\n<p>\n  In a phase three trial, the company's treatment combining bezuclastinib with sunitinib showed 16.5 months median progression free survival compared to 9.2 months for sunitinib monotherapy. The safety profile was also well tolerated. \n</p>\n<p>\n  \"The bezuclastinib combination is poised to become the new standard of care for treatment of second-line GIST patients,\" said Cogent Chief Executive Andrew Robbins. \n</p>\n<p>\n  The company said it planned to submit a new drug application for bezuclastinib in the first half of next year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 10, 2025 09:08 ET (14:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴資本持倉","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2582687216","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582687216","pubTimestamp":1762783680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Cogent Biosciences soared after the company reported positive trial data for its treatment of Gastrointestinal Stromal Tumors that surpassed its expectations.The stock more than doubled in premarket trading to $30.97 Monday after closing Friday up 90% this year.In a phase three trial, the company's treatment combining bezuclastinib with sunitinib showed 16.5 months median progression free survival compared to 9.2 months for sunitinib monotherapy. The safety profile was also well tolerated.\"The bezuclastinib combination is poised to become the new standard of care for treatment of second-line GIST patients,\" said Cogent Chief Executive Andrew Robbins.The company said it planned to submit a new drug application for bezuclastinib in the first half of next year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","BK4089":"非传统电信运营商","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","COGT":"Cogent Biosciences, Inc.","CCOI":"Cogent Communications Group"},"translate_title":"Cogent Biosciences股价因肿瘤药物试验结果呈阳性而翻倍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CCOI":1.5,"COGT":0.9},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  Shares of Cogent Biosciences soared after the company reported positive trial data for its treatment of Gastrointestinal Stromal Tumors that surpassed its expectations. \n\n\n  The stock more than doubled in premarket trading to $30.97 Monday after closing Friday up 90% this year. \n\n\n  In a phase three trial, the company's treatment combining bezuclastinib with sunitinib showed 16.5 months median progression free survival compared to 9.2 months for sunitinib monotherapy. The safety profile was also well tolerated. \n\n\n  \"The bezuclastinib combination is poised to become the new standard of care for treatment of second-line GIST patients,\" said Cogent Chief Executive Andrew Robbins. \n\n\n  The company said it planned to submit a new drug application for bezuclastinib in the first half of next year. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 09:08 ET (14:08 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}